quilt-3.055: a study of combination immunotherapies in patients who have previously received treatment with immune checkpoint inhibitors

Conditions: Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma; Head and Neck Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Renal Cell Carcinoma; Gastric Cancer; Cervical Cancer; Hepatocellular Carcinoma; Microsatellite Instability; Mismatch Repair Deficiency; Colorectal Cancer

Summary: this phase 2b, multicohort, open-label clinical trial (quilt-3.055) evaluates combination immunotherapies in patients with various advanced solid tumors who have progressed following prior pd-1/pd-l1 checkpoint inhibitor therapy. the trial includes six cohorts: cohorts 1-4: patients who progressed after an initial response (pr or cr) to prior pd-1/pd-l1 therapy, receiving combination therapy with n-803 and a pd-1/pd-l1 checkpoint inhibitor. (closed to enrollment) cohort 5: patients who progressed while receiving treatment in cohorts 1-4; they receive combination therapy with n-803, a pd-1/pd-l1 checkpoint inhibitor, and pd-l1 t-hank cells.(closed to enrollment) cohort 6a \& 6b: patients with acquired resistance to prior pd-1/pd-l1 therapy; they receive combination therapy with n-803, docetaxel, and either pembrolizumab (6a) or nivolumab (6b). treatment is administered for up to two years or until disease progression, and participants are closely monitored for adverse events (aes), including immune-related aes, with specific dose modifications outlined. the primary endpoint is objective response rate (orr) assessed by recist v1.1. the study uses simon's two-stage design for cohorts 1-3 to determine the optimal dose and further assesses safety and efficacy endpoints for all cohorts.

only cohort 6 is recruiting.

Eligibility criteria:
inclusion criteria (cohort 6 only) 1. age ≥ 18 years old. 2. able to understand and provide a signed informed consent that fulfills the relevant irb/iec guidelines. 3. pathologically confirmed stage iv nsclc disease. 4. have received exactly 1 anti-pd-1 or anti-pd-l1 therapy (either pembrolizumab or nivolumab) for advanced disease (stage iv or recurrent disease, or stage i-iii disease in certain circumstances) outlined below. anti-pd-1 or anti-pd-l1 therapy may have been given alone or in combination with other therapy. a. for those participants who received neoadjuvant, adjuvant, and/or consolidation anti-pd-1 or anti-pd-l1 therapy for stage i-iii disease: if they had disease progression within (≤) 365 days from initiation (cycle 1 day 1) of anti-pd-1 or anti-pd-l1 therapy, this counts as the single allowed anti-pd-1 or anti-pd-l1 therapy for advanced disease or if they had disease progression more than (\>) 365 days from initiation (cycle 1 day 1) of anti-pd-1 or anti-pd-l1 therapy, this is not considered anti-pd-1 or anti-pd-l1 therapy for advanced disease. these participants must have received anti-pd-1 or anti-pd-l1 therapy for stage iv or recurrent disease. 5. have reported disease progression (in the opinion of the treating physician) more than (\>) 84 days following initiation (cycle 1 day 1) of their most recent anti-pd-1 or anti-pd-l1 therapy (either pembrolizumab or nivolumab). 6. participants who received anti-pd-1 or anti-pd-l1 therapy for stage iv or recurrent disease, must have had a best response of sd, pr or cr (in the opinion of the treating physician) on the anti- pd-1 or anti-pd-l1 therapy (either nivolumab or pembrolizumab) for stage iv or recurrent disease. 7. participants with a known sensitizing mutation for which an - approved targeted therapy for nsclc exists (e.g., egfr, alk, ros1, braf, ret, ntrk, kras, her2 and met sensitizing mutations), must have previously received at least 1 of the approved therapy(s). prior targeted therapy for participants with targetable alterations is allowed if all other eligibility criteria are also met. 8. ecog performance status of 0 to 2. 9. measurable tumor lesions according to recist v1.1. 10. ability to attend required study visits and return for adequate follow-up, as required by this protocol. 11. agreement to practice effective contraception for female participants of child-bearing potential and non-sterile males. female participants of child-bearing potential must agree to use effective contraception for up 7 months after completion of therapy, and non-sterile male participants must agree to use a condom for up to 7 months after treatment. effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), orals, injectables, 2 forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (iuds), and hormonal therapy. exclusion criteria (cohort 6 only) 1. systemic autoimmune disease currently requiring treatment (e.g., lupus erythematosus, rheumatoid arthritis, addison's disease, or autoimmune disease associated with lymphoma). the participant must have been off treatment for 180 days. 2. history of organ transplant requiring immunosuppression; or history of pneumonitis or interstitial lung disease requiring treatment with systemic steroids; or a history of receiving systemic steroid therapy or any other immunosuppressive medication ≤ 3 days prior to study initiation. daily steroid replacement therapy (eg, prednisone or hydrocortisone) and corticosteroids used to manage aes are permitted. 3. history of known active hepatitis b or c infection. 4. active infection requiring antibiotic therapy. 5. history of or active inflammatory bowel disease (e.g., crohn's disease, ulcerative colitis). 6. had major surgery within 28 days prior to study enrollment. participants must have fully recovered from the effects of prior surgery in the opinion of the treating investigator. 7. inadequate organ function, evidenced by the following laboratory results: 1. absolute lymphocyte count \< institutional uln. 2. absolute neutrophil count (anc) \< 1,500 cells/mm3. 3. platelet count \< 100,000 cells/mm3. 4. total bilirubin greater than the upper limit of normal (uln; unless the participant has documented gilbert's syndrome). 5. aspartate aminotransferase (ast \[sgot\]) or alt (sgpt) \> 1.5 × uln. 6. alkaline phosphatase (alp) levels \> 2.5 × uln. 7. hemoglobin \< 9.0 g/dl. 8. serum creatinine \> 2.0 mg/dl or 177 μmol/l or creatinine clearance \< 40 ml/min (using the cockcroft-gault formula below): female = \[(140 - age in years) × weight in kg × 0.85\] / \[72 × serum creatinine in mg/dl\] male = \[(140 - age in years) × weight in kg × 1.00\] / \[72 × serum creatinine in mg/dl\] 8. have any of following: 1. cirrhosis at a level of child-pugh b (or worse); 2. cirrhosis (any degree) and a history of hepatic encephalopathy; or 3. clinically meaningful ascites resulting from cirrhosis. clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis. 9. participation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to the start of treatment on this study, except for hormone lowering therapy in participants with hormone-sensitive cancer. 10. assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol. 11. pregnant and nursing women.

Keywords: pembrolizumab nivolumab non-small cell lung cancer (nsclc) immunotherapy interleukin-15 pd-1 checkpoint inhibitor alt-803 atezolizumab avelumab small cell lung cancer (sclc) urothelial carcinoma head and neck squamous cell carcinoma (hnscc) merkel cell carcinoma (mcc) melanoma renal cell carcinoma (rcc) gastric cancer cervical cancer hepatocellular carcinoma (hcc) microsatellite instability-high (msi-h) pd-l1 checkpoint inhibitor mismatch repair deficient (dmmr) solid tumor cancer colorectal cancer (crc) durvalumab pd-l1 t-hank n-803 keytruda opdivo imfinzi bavencio tecentriq